Search Bar & Filters
Found 17 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the effectiveness and safety of zanidatamab combined with a physicians choice of chemotherapy compared to trastuzumab combined with chemotherapy in treating adults with metastatic HER2-positive breast cancer who have either progressed on or cannot tolerate previous trastuzumab deruxtecan T-DXd treatment. Zanidatamab has shown promising results against various HER2-positive advanced tumors, including metastatic breast cancer, and may serve as a potential treatment option for these patients. The study also investigates patient-reported tolerability and physical functioning, as well as the pharmacokinetics and immune response to zanidatamab with chemotherapy. Participants will be randomly assigned to receive either zanidatamab or trastuzumab, each given by intravenous infusion alongside one of several chemotherapy options chosen by the physician eribulin, vinorelbine, gemcitabine, or capecitabine the latter is taken orally. Treatment will be administered according to the assigned group, and the study is open-label and multicenter, designed to compare these two treatment combinations in this patient population. During the study, participants will undergo regular assessments to monitor disease progression using imaging criteria RECIST version 1.1, evaluate survival, treatment response, and duration of response. Safety and side effects will be tracked through adverse event reporting and patient questionnaires on symptoms and physical function. Blood samples will be collected to study drug levels and immune reactions. Participants will be followed until disease progression, death, or for up to approximately 44 months for key outcomes, with overall survival monitored for up to about 80 months.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the effects of the drug EYU688 compared with a placebo in adults aged 18 to 60 who have dengue fever. This study aims to understand how EYU688 influences dengue viral load, fever clearance time, and clinical symptoms. It is a phase 2 randomized, participant- and investigator-blinded, placebo-controlled trial with two parallel cohorts differing by pharmacokinetic sampling schedules. Participants will receive EYU688 or a matching placebo orally. The study includes two cohorts running simultaneously one with intensive pharmacokinetic sampling and one with sparse sampling, to assess the drugs behavior in the body. Treatment is administered during the initial days following fever onset, with careful monitoring of viral load and clinical signs. Throughout the study, participants will undergo regular assessments including viral load measurements, fever monitoring, clinical symptom evaluations, and laboratory tests such as blood counts and liver enzyme levels. Safety monitoring for adverse events will continue through Day 35. The primary outcome is reduction in viral load at 48 hours after treatment start. The total trial period includes follow-up until Day 35, with ongoing evaluation of clinical recovery and safety.
Actively Recruiting
Researchers are evaluating zipalertinib, a new EGFR tyrosine kinase inhibitor TKI, compared to a placebo in people with early stage non-small cell lung cancer NSCLC who have uncommon EGFR mutations and have had their tumors completely surgically removed. The study focuses on participants with specific uncommon EGFR mutations, including exon 20 insertions and others in exons 18-21, aiming to understand the treatments impact on disease-free survival after surgery. Participants are randomly assigned to receive either zipalertinib or a matching placebo, both taken orally twice daily. Treatment continues until certain criteria for stopping are met. An independent committee will monitor safety during the study. The study plans to include about 360 participants and will last up to 5 years for measuring outcomes. Throughout the trial, participants will be closely monitored with brain imaging before starting treatment to ensure no brain metastases. Researchers will assess disease-free survival as their main outcome over up to 5 years, along with overall survival and quality of life measures. Safety will be evaluated through tracking adverse events, lab tests, vital signs, heart function via ECG and scans, and quality of life questionnaires. Participants will have regular visits for treatment and assessment over the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide at different dose levels compared to a placebo in adults with uncontrolled moderate to severe asthma. The study aims to understand how brenipatide impacts asthma control and exacerbation rates over time. This phase 2, randomized, double-blind trial involves participants aged 18 to 75 years who have a history of asthma and recent asthma exacerbations. Participants will receive either one of two doses of brenipatide or a placebo, all administered by subcutaneous injection. The treatment period lasts 52 weeks, during which the effects of the study drug on asthma symptoms and lung function will be monitored. The study includes screening, treatment, and follow-up phases, with the overall participation lasting about 65 weeks. During the trial, participants will undergo assessments such as lung function tests, health questionnaires, and monitoring for asthma exacerbations and medication use. Blood samples may be collected to study the drugs behavior in the body and the immune response. Researchers will track safety and treatment effects throughout the study and during follow-up to understand the long-term impact of brenipatide on asthma control.
Actively Recruiting
Researchers are evaluating the efficacy and safety of QMF149 a combination of indacaterol acetate and mometasone furoate compared to budesonide in children aged 6 to less than 12 years who have asthma. This Phase 3, double-blind, randomized, active-controlled crossover study aims to determine whether QMF149 is superior in improving lung function measured by FEV1 in these children, who have at least 50% of the predicted normal value of FEV1. Participants undergo two treatment periods, each lasting 12 weeks, receiving either QMF149 7540 mcg once daily via Breezhaler or budesonide 200 mcg once daily via Breezhaler in a crossover design. The study includes a screening period of up to 3 weeks, a 3-week run-in period with fluticasone propionate 50 mcg twice daily, a 3-week washout period with the same medication, and a 4-week safety follow-up during which participants return to standard care. The total study duration is up to 37 weeks. Throughout the study, participants will attend visits at defined intervals, including screening, run-in, treatment, washout, and follow-up periods. Researchers will assess lung function changes FEV1, asthma control questionnaire scores, peak expiratory flow rates, rescue medication use, and monitor adverse events. Safety information and survival status will be collected after the follow-up period to ensure thorough evaluation of both treatments.
Actively Recruiting
Researchers are evaluating an investigational drug called REGN5668 alone or combined with cemiplimab, cemiplimab plus fianlimab, or ubamatamab, with or without sarilumab, in adult women with ovarian or uterine cancers. The study aims to find the highest safe dose of these combinations and to learn about their safety and potential to treat these cancers. It includes two parts Part 1 focuses on dose escalation to determine safe dosing, and Part 2 uses those doses to further evaluate treatment effects, including women with uterine cancer who participate only in Part 2. Participants receive REGN5668 alone or in combination with cemiplimab, cemiplimab plus fianlimab, or ubamatamab following the protocol. The study evaluates multiple treatment combinations sequentially, observing side effects and how the drugs work in the body. The study drugs are administered according to the studys schedule, and dosing adjustments may occur based on safety findings in Part 1, with Part 2 using selected doses for further evaluation. Throughout participation, researchers monitor safety by tracking dose-limiting toxicities, adverse events, laboratory abnormalities, and deaths over up to five years. They measure drug concentrations in the blood and assess treatment response using RECIST criteria. Participants will undergo assessments such as blood tests and imaging to evaluate cancer response and side effects. The total study duration can last up to five years, including long-term safety follow-up and monitoring of treatment effects.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab in children aged 5 to under 12 years with severe uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids and at least one other asthma controller medication, with or without oral corticosteroids. This phase 3, multicenter, randomized, double-blind study aims to compare tezepelumab with a placebo to better understand its impact on asthma control in this age group. Participants will be randomly assigned in a 21 ratio to receive either subcutaneous injections of tezepelumab or a matching placebo over a 52-week double-blind treatment period. Before treatment, there is a 4 to 6 week screening and run-in period. After the treatment period, a 12-week off-treatment follow-up occurs for those not continuing. Eligible participants may enter an optional 104-week open-label extension to receive tezepelumab with an additional 12-week follow-up after that. During the study, participants will undergo various assessments including lung function tests, asthma symptom tracking, quality of life questionnaires, and blood tests to measure biomarkers and drug levels. Researchers will monitor asthma exacerbations, rescue medication use, and healthcare visits. Safety will be closely observed throughout the study and follow-up periods. Total participation may last over two years for those in the extension phase.
Actively Recruiting
Researchers are evaluating the effects of tozorakimab, a drug given by injection under the skin, in adults with uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids. This phase IIb study is designed to find the right dose and assess how safe and effective tozorakimab is for reducing severe asthma attacks over a period of 26 to 52 weeks. Participants will be randomly assigned to receive one of two doses of tozorakimab or a placebo, all given subcutaneously. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The treatment period lasts up to 52 weeks with regular monitoring. The study will measure asthma exacerbation rates, lung function changes, asthma control, quality of life, and drug levels in the blood. During the trial, participants will complete daily asthma diaries to track symptoms and medication use, and attend visits for lung function tests, questionnaires, and blood samples. Safety and antibody responses to the drug will be monitored throughout. Participation lasts up to about one year, including screening and treatment, with regular visits to assess health and response to the study drug.
Actively Recruiting
Researchers are assessing the long-term safety and tolerability of the Port Delivery System with ranibizumab PDS in people with neovascular age-related macular degeneration nAMD who have completed previous related studies or certain visits within those studies. The trial includes two sub-studies to evaluate specific aspects one tests the effectiveness of transscleral photocoagulation to reduce vitreous hemorrhages after PDS implantation, and the other assesses the safety of re-implantation with an updated PDS device. Participants receive the PDS implant with ranibizumab at a concentration of 100 mgmL, administered through refill-exchange procedures at set intervals varying by previous study involvement, typically every 24 weeks with some switching to every 12 weeks later in the trial. The sub-studies involve additional treatments such as laser therapy or re-implantation and follow-up for up to 72 weeks. Treatment schedules and monitoring differ depending on enrollment cohorts and prior participation. Throughout the study, participants undergo regular assessments including eye exams, imaging, and monitoring for adverse events related to the PDS implant and ranibizumab treatment. The study tracks vision changes, ocular health, device safety, and any complications over periods up to 240 weeks or longer if regulatory approval is pending. Participants adherence to visit schedules and safety measures are closely observed as part of the trials long-term evaluation.
1-10 of 17
1